Oncology – Page 11 – Medical News Asia

MURANO: off-drug progression-free survival after 2 years venetoclax plus 6 cycles Rituximab

5 December 2018/0 Comments/in Haematology, ASH 2018 Annual Meeting, Oncology, Chemotherapy, Immunotherapy, Targeted Therapies/by scienterrific

On the first day of the 2018 American Society of Hematology (ASH) Annual Meeting, an additional year of follow-up data from the practice-changing MURANO study were presented to the audience by Professor John F. Seymour. In the trial’s setting of relapsed/refractory (R/R) chronic lymphocytic leukaemia (CLL), the non-chemo-containing regimen venetoclax (Venclexta®, AbbVie/Roche) plus rituximab was associated with maintained superior progression-free survival (PFS) and overall survival (OS) over standard-of-care chemoimmunotherapy with bendamustine plus rituximab. At the same time, a durable post-treatment disease control is also attainable with the fixed-duration chemo-free regimen.

TIGR®Matrix shows promising results when used for incisional hernia prevention in septic patients undergoing laparoscopy

4 December 2018/1 Comment/in Medical News Asia, Oncology, Surgery/by scienterrific

Onlay mesh placement of the synthetic and fully resorbable TIGR®Matrix surgical mesh (Novus Scientific AB, Uppsala — Sweden) for the prevention of incisional hernia in septic patients undergoing emergency laparoscopy showed encouraging efficacy and safety in a small retrospective study, as presented during the XXVIII Waterford Surgical October Club Meeting.

Gilteritinib (Xospata®) FDA approved for relapsed or refractory AML harbouring FLT3 mutations

29 November 2018/0 Comments/in US FDA Onc\Haem Approvals, Haematology, Targeted Therapies/by scienterrific

On 28 November 2018, the FDA approved gilteritinib (Xospata® [ASP2215], Astellas) for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukaemia (AML) harbouring FLT3 mutations as confirmed by an FDA-approved companion diagnostic test (CDx).

TKR inhibitor larotrectinib (Vitrakvi®) FDA approved for cancers with NTRK gene fusion

28 November 2018/0 Comments/in US FDA Onc\Haem Approvals, Head and Neck Cancer, Targeted Therapies/by scienterrific

On 26 November 2018, the FDA granted accelerated approval to the first-in-class tropomyosin receptor-kinase (TRK) inhibitor larotrectinib (Vitrakvi®, Loxo Oncology/Bayer) for the treatment of adult and paediatric patients with solid tumours that are metastatic or not amenable to surgery, harbour the neurotrophic receptor tyrosine kinase (NTRK) gene fusion in the absence of known acquired resistance mutations, and whose cancer progressed following treatment or for whom are no satisfactory other treatment options available.

FDA Approves Truxima as Biosimilar to Rituxan

28 November 2018/0 Comments/in US FDA Onc\Haem Approvals, Haematology, Oncology, Chemotherapy, Targeted Therapies/by Stijn van den Borne, MSc

Venetoclax plus azacitidine, decitabine, or low-dose cytarabine FDA approved in elderly AML patients

23 November 2018/0 Comments/in US FDA Onc\Haem Approvals, Haematology, Chemotherapy, Targeted Therapies/by scienterrific

On 21 November 2018, the FDA granted accelerated approval to venetoclax (Venclexta®, AbbVie/Genentech) in combination with either azacitidine, or decitabine, or low-dose cytarabine (LDAC), for the treatment of newly-diagnosed acute myeloid leukaemia (AML) patients ≥75 years old or in patients with comorbidities precluding intensive induction chemotherapy.

Glasdegib plus low-dose cytarabine (LDAC) approved in elderly AML patients

23 November 2018/0 Comments/in US FDA Onc\Haem Approvals, Haematology, Chemotherapy, Targeted Therapies/by scienterrific

On 21 November 2018, the FDA approved glasdegib (Daurismo®, Pfizer) in combination with low-dose cytarabine (LDAC), for the treatment of newly-diagnosed acute myeloid leukaemia (AML) in patients of 75 years or older and in patients with comorbidities contraindicating intensive induction chemotherapy.

The Emerging Role of Yttrium-90 in Primary and Metastatic Liver Cancer

22 November 2018/Enter your password to view comments./in Gastrointestinal Cancer, Oncology, Radioactive Drugs, Radiology/by Adrian YIP

There is no excerpt because this is a protected post.

Emapalumab FDA approved in adult and paediatric patients with primary hemophagocytic lymphohistiocytosis

21 November 2018/0 Comments/in US FDA Onc\Haem Approvals, Haematology/by scienterrific

On 20 November 2018, the FDA approved the interferon-γ neutralising monoclonal antibody emapalumab (Gamifant®, Novimmune) for the treatment of adult and paediatric (newborn and older) patients with refractory, recurrent, or progressive primary haemophagocytic lymphohistiocytosis (HLH) or in patients intolerant to conventional HLH therapy.

Brentuximab vedotin (Adcetris®) plus chemotherapy approved for several CD30 expressing lymphomas

21 November 2018/0 Comments/in US FDA Onc\Haem Approvals, Haematology, Chemotherapy/by scienterrific

On 16 November, 2018, the FDA approved brentuximab vedotin (Adcetris®, Seattle Genetics) in combination with chemotherapy for the treatment of previously untreated systemic anaplastic large cell lymphoma (sALCL) and other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma (AITL) and PTCL not otherwise specified (PTCL-NOS).